Mesoblast Ltd ADR (MESO)

$17.19 -0.06 (-0.35%)
Market Cap 2.23B
Revenue (ttm) 17.20M
Net Income (ttm) -102.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -593.84%
Debt to Equity Ratio 0.20
Volume 152,000
Avg Vol 222,768
Day's Range N/A - N/A
Shares Out 129.03M
Stochastic %K 16%
Beta 2.14
Analysts Strong Sell
Price Target $35.00

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
Mani86
Mani86 Feb. 2 at 12:56 AM
$MESO $XBI https://www.youtube.com/watch?v=mxHcegsJyhg&t=1055s Game changing technology with these MSC and there effect on inflammatory tissues
0 · Reply
Mani86
Mani86 Jan. 31 at 10:03 AM
$MESO $XBI https://www.fool.com.au/2026/01/30/could-mesoblast-shares-hit-4-45-in-2026/
1 · Reply
Mani86
Mani86 Jan. 30 at 7:07 AM
$MESO https://www.crweworld.com/article/news-provided-by-globenewswire/3781925/ryoncil-net-revenues-increase-for-the-quarter-to-us30m It will be cash flow positive by mid year 2026. Time to accumulate on dips.
0 · Reply
Portman62
Portman62 Jan. 27 at 4:29 PM
$MESO no down side here, $22.00 should be a breeze.
0 · Reply
Mani86
Mani86 Jan. 27 at 12:24 PM
$MESO https://www.marketindex.com.au/asx/msb/announcements/real-world-experience-with-ryoncil-shows-84-early-survival-3A685893 Keep hitting goals !!!
0 · Reply
Mani86
Mani86 Jan. 21 at 12:19 AM
$MESO$XBI BREAKING: Mesoblast ($MESO) just secured a vital regulatory win for its Stem Cell therapy (rexlemestrocel-L). The FDA confirmed the path to approval for Chronic Low Back Pain (CLBP)—a market of 7 million US patients. The Alpha: • Primary Endpoint: FDA accepted 12-month pain reduction as the bar for approval. • Label Upside: FDA is open to including "Opioid Reduction" claims. Data shows patients were 3x more likely to quit opioids completely vs placebo. This positions $MESO not just as a pain play, but as a regenerative solution to the Opioid Crisis. Confirmatory Phase 3 is >50% enrolled.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 10:41 PM
$MESO RSI: 36.93, MACD: -0.0688 Vol: 0.98, MA20: 18.69, MA50: 17.43 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Mani86
Mani86 Jan. 20 at 12:20 PM
$XBI $MESO FDA in alignment on back pain trial with Rex L , hopefully another approval in a year.
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 19 at 8:50 PM
$MESO FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy "Mesoblast is seeking FDA approval for rexlemestrocel-L based on reduction in CLBP through 12 months. Comparing outcomes between rexlemestrocel-L and placebo from MSB-DR003 trial, FDA acknowledged that the effects on pain intensity appear to favor the active arm. FDA also confirmed that a clinically meaningful reduction in pain intensity in the active arm versus placebo at 12 months can support product efficacy and stated that the robust results on opioid reduction from at least one adequate and well controlled trial could be included in the Clinical Studies section of product labeling."
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 19 at 3:54 PM
$MESO Share Price: $17.46 Contract Selected: Jan 15, 2027 $15 Calls Buy Zone: $5.10 – $6.30 Target Zone: $9.63 – $11.77 Potential Upside: 78% ROI Time to Expiration: 360 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on MESO
Ryoncil® Net Revenues Increase for the Quarter to US$30M

Jan 28, 2026, 6:54 PM EST - 5 days ago

Ryoncil® Net Revenues Increase for the Quarter to US$30M

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

Jan 26, 2026, 6:45 PM EST - 7 days ago

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

Jan 18, 2026, 7:01 PM EST - 15 days ago

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

Jan 8, 2026, 6:46 PM EST - 25 days ago

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

Mesoblast Announces Changes to Board of Directors' Leadership Roles

Jan 1, 2026, 6:02 PM EST - 4 weeks ago

Mesoblast Announces Changes to Board of Directors' Leadership Roles

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Dec 29, 2025, 6:57 PM EST - 5 weeks ago

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Dec 11, 2025, 6:22 PM EST - 7 weeks ago

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Mesoblast Participation at Piper Sandler Conference

Dec 3, 2025, 6:10 PM EST - 2 months ago

Mesoblast Participation at Piper Sandler Conference

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

Nov 24, 2025, 6:39 PM EST - 2 months ago

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

Nov 20, 2025, 6:32 PM EST - 2 months ago

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

Nov 17, 2025, 1:52 AM EST - 2 months ago

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Nov 4, 2025, 6:40 PM EST - 3 months ago

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

Oct 19, 2025, 7:48 PM EDT - 3 months ago

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Oct 6, 2025, 7:24 PM EDT - 4 months ago

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Oct 6, 2025, 8:09 AM EDT - 4 months ago

Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session

IONQ QBTS QUBT RGTI

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Oct 2, 2025, 9:04 PM EDT - 4 months ago

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Sep 26, 2025, 1:49 AM EDT - 4 months ago

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

Sep 14, 2025, 9:18 PM EDT - 5 months ago

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Sep 3, 2025, 9:47 PM EDT - 5 months ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Aug 29, 2025, 12:27 PM EDT - 5 months ago

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Aug 28, 2025, 8:24 PM EDT - 5 months ago

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Successful Commercial Launch of Ryoncil®

Jul 17, 2025, 8:38 PM EDT - 7 months ago

Successful Commercial Launch of Ryoncil®

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Jul 1, 2025, 8:46 AM EDT - 7 months ago

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Jun 30, 2025, 8:36 PM EDT - 7 months ago

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Jun 11, 2025, 9:24 PM EDT - 8 months ago

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

May 14, 2025, 10:57 PM EDT - 9 months ago

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

May 5, 2025, 2:44 AM EDT - 9 months ago

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Apr 29, 2025, 8:53 PM EDT - 9 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Apr 28, 2025, 7:44 PM EDT - 10 months ago

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Apr 16, 2025, 9:20 PM EDT - 10 months ago

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Apr 3, 2025, 6:58 PM EDT - 10 months ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Apr 2, 2025, 7:15 PM EDT - 10 months ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

First Three Children to Commence Treatment With Ryoncil®

Mar 30, 2025, 7:39 PM EDT - 11 months ago

First Three Children to Commence Treatment With Ryoncil®

Ryoncil® is Now Available for Purchase in the United States

Mar 26, 2025, 8:19 PM EDT - 11 months ago

Ryoncil® is Now Available for Purchase in the United States

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mar 13, 2025, 7:42 PM EDT - 11 months ago

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mar 12, 2025, 7:30 AM EDT - 11 months ago

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Feb 28, 2025, 11:38 AM EST - 1 year ago

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Feb 26, 2025, 5:30 PM EST - 1 year ago

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Financial Results and Corporate Update Webcast

Feb 25, 2025, 6:13 PM EST - 1 year ago

Mesoblast Financial Results and Corporate Update Webcast

Dr. Gregory George MD PhD Joins Mesoblast Board

Feb 23, 2025, 6:33 PM EST - 1 year ago

Dr. Gregory George MD PhD Joins Mesoblast Board

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Feb 13, 2025, 6:37 PM EST - 1 year ago

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Ryoncil® Commercial Launch Update and Product Pipeline

Jan 30, 2025, 7:11 PM EST - 1 year ago

Ryoncil® Commercial Launch Update and Product Pipeline

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Jan 30, 2025, 6:20 PM EST - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Dec 19, 2024, 6:38 AM EST - 1 year ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

Dec 18, 2024, 7:08 PM EST - 1 year ago

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Dec 18, 2024, 4:58 PM EST - 1 year ago

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Mesoblast to be Added to Nasdaq Biotechnology Index

Dec 18, 2024, 7:30 AM EST - 1 year ago

Mesoblast to be Added to Nasdaq Biotechnology Index

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dec 12, 2024, 12:08 PM EST - 1 year ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

CAPR XBI

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Dec 4, 2024, 6:32 PM EST - 1 year ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Dec 2, 2024, 6:20 PM EST - 1 year ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Mani86
Mani86 Feb. 2 at 12:56 AM
$MESO $XBI https://www.youtube.com/watch?v=mxHcegsJyhg&t=1055s Game changing technology with these MSC and there effect on inflammatory tissues
0 · Reply
Mani86
Mani86 Jan. 31 at 10:03 AM
$MESO $XBI https://www.fool.com.au/2026/01/30/could-mesoblast-shares-hit-4-45-in-2026/
1 · Reply
Mani86
Mani86 Jan. 30 at 7:07 AM
$MESO https://www.crweworld.com/article/news-provided-by-globenewswire/3781925/ryoncil-net-revenues-increase-for-the-quarter-to-us30m It will be cash flow positive by mid year 2026. Time to accumulate on dips.
0 · Reply
Portman62
Portman62 Jan. 27 at 4:29 PM
$MESO no down side here, $22.00 should be a breeze.
0 · Reply
Mani86
Mani86 Jan. 27 at 12:24 PM
$MESO https://www.marketindex.com.au/asx/msb/announcements/real-world-experience-with-ryoncil-shows-84-early-survival-3A685893 Keep hitting goals !!!
0 · Reply
Mani86
Mani86 Jan. 21 at 12:19 AM
$MESO$XBI BREAKING: Mesoblast ($MESO) just secured a vital regulatory win for its Stem Cell therapy (rexlemestrocel-L). The FDA confirmed the path to approval for Chronic Low Back Pain (CLBP)—a market of 7 million US patients. The Alpha: • Primary Endpoint: FDA accepted 12-month pain reduction as the bar for approval. • Label Upside: FDA is open to including "Opioid Reduction" claims. Data shows patients were 3x more likely to quit opioids completely vs placebo. This positions $MESO not just as a pain play, but as a regenerative solution to the Opioid Crisis. Confirmatory Phase 3 is >50% enrolled.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 10:41 PM
$MESO RSI: 36.93, MACD: -0.0688 Vol: 0.98, MA20: 18.69, MA50: 17.43 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Mani86
Mani86 Jan. 20 at 12:20 PM
$XBI $MESO FDA in alignment on back pain trial with Rex L , hopefully another approval in a year.
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 19 at 8:50 PM
$MESO FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy "Mesoblast is seeking FDA approval for rexlemestrocel-L based on reduction in CLBP through 12 months. Comparing outcomes between rexlemestrocel-L and placebo from MSB-DR003 trial, FDA acknowledged that the effects on pain intensity appear to favor the active arm. FDA also confirmed that a clinically meaningful reduction in pain intensity in the active arm versus placebo at 12 months can support product efficacy and stated that the robust results on opioid reduction from at least one adequate and well controlled trial could be included in the Clinical Studies section of product labeling."
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 19 at 3:54 PM
$MESO Share Price: $17.46 Contract Selected: Jan 15, 2027 $15 Calls Buy Zone: $5.10 – $6.30 Target Zone: $9.63 – $11.77 Potential Upside: 78% ROI Time to Expiration: 360 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Mani86
Mani86 Jan. 19 at 2:50 AM
$MESO https://www.marketindex.com.au/asx/msb/announcements/fda-confirms-path-to-approval-for-clbp-3A685565
0 · Reply
Mani86
Mani86 Jan. 13 at 11:56 PM
$MESO https://www.iheart.com/podcast/269-inside-the-texas-heart-stu-171155673/episode/advancements-in-cardiovascular-care-exploring-cell-based-313032006/
0 · Reply
Real_Men_of_Genius
Real_Men_of_Genius Jan. 13 at 2:48 PM
$MESO https://investorsmedia.mesoblast.com/ More shares, but not all understand what this is about, but it's just a reason to take it down.
0 · Reply
zipperson
zipperson Jan. 12 at 7:12 PM
$MESO
0 · Reply
Real_Men_of_Genius
Real_Men_of_Genius Jan. 12 at 3:01 PM
$MESO Great day to buy some IMO.
0 · Reply
Mani86
Mani86 Jan. 12 at 12:09 AM
$MESO https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation
0 · Reply
Yor0311
Yor0311 Jan. 10 at 9:37 AM
$MESO https://x.com/mesoblast/status/2009633761952993402?s=61&t=ZOuYg6MVxMLTogSyQFkGMg
1 · Reply
OpenOutcrier
OpenOutcrier Jan. 9 at 1:33 PM
$MESO (+8.0% pre) Mesoblast Boosts Ryoncil Sales 60% and Secures Cheaper US$125M Financing https://ooc.bz/l/89178
0 · Reply
Mani86
Mani86 Jan. 9 at 12:02 PM
$MESO $XBI https://www.businessnewsaustralia.com/articles/mesoblast-shares-hit-five-year-high-as-ryoncil-quarterly-sales-surge-60-per-cent-to-52m.html
0 · Reply
Fenderstrat68
Fenderstrat68 Jan. 9 at 2:04 AM
$MESO has anyone with good knowledge of this space have any range of where sales could be, say 12/24 months from now? I ve been focused on a couple other bios and bought some MESO a while back, but have not been able to dive as deep as I d like. Any good pointers would be appreciated! Thanks
4 · Reply
AlertsAndNews
AlertsAndNews Jan. 9 at 12:31 AM
$MESO good for them. Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
0 · Reply
Mani86
Mani86 Jan. 9 at 12:10 AM
$MESO Mesoblast just delivered a very strong commercial update. Ryoncil sales jumped 60% QoQ to US$35.1M, confirming real revenue momentum, not just promise. The company has cleaned up its balance sheet, repaid old expensive debt, and locked in a flexible US$125M facility without putting IP or assets at risk. Importantly, Ryoncil is already FDA-approved and selling, with the adult indication now in trials, which management says is a market ~3x larger than pediatrics. Strong sales, improving finances, long patent life (to 2044+), and upcoming adult expansion make this one of the clearest biotech commercialisation stories on the ASX.
0 · Reply